Biotech Values

[DewDiligence]

Regarding your other point in #msg-76009165 (that the subpopulation for which I brought up Zebra’s Law is not the main population to be addressed in further CDX-011 studies), I ought to clarify that I consider it an instance of Zebra’s Law not only if a program that shouldn’t advance advances, but also if a program that shouldn’t advance in a particular subgroup advances in that subgroup. So, in this sense, Zebra’s Law can legitimately be applied to what iwfal is talking about in #msg-76005421.

Again, none of the above should be taken as implying that I have a bearish opinion of CLDX or CDX-011.